Aegerion (AEGR) Receives FDA Approval for JUXTAPID Caps
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Analyst Bullish as Aegerion (AEGR) Drug Approved with Broad Label
December 26, 2012 9:23 AM ESTOn Monday Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR) announced that the U.S. Food & Drug Administration approved JUXTAPID (lomitapide) capsules as an adjunct to a low-fat diet and other lipid-lowering treatments. In response, Leerink Swann reiterated an Outperform rating on Aegerion and raised its price target to $30.00 (from $25.00).
"Lead agent Juxtapid (lomitapide) is a smallmolecule microsomal triglyceride transfer protein (MTP) inhibitor with the unique ability to limit... More
